Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog



Biogenerics market presents new commercial opportunity

11 Jun 04

With several blockbuster biological products approaching patent expiry and the emergence of new approval pathways, the biogenerics segment represents an attractive opportunity for companies looking to escape intensifying competition in the commodity generics sector. However, with the biotech industry preparing significant opposition to any new regulatory initiatives, barriers to market entry could remain high.

Off-Label Usage

25 May 04

This conference clarifies the risks that impede healthy practice, knowledgeable planning, and profits from off-label usage.
Joddie Vaughn

Consultant Questionnaire - Nick Langley, Advance

21 May 04

As the difficulty of the reps role increases, Pharmiweb talks to the people whose role it is to get the best people for the job. This week Nick Langley of Advance.
Mark Stacey

Safety and Efficacy Biomarkers

21 May 04

To aid in your drug development efforts, Pharmaceutical Education Associates is proud to present our inaugural “Identification and Validation of Safety and Efficacy Biomarkers” conference. Ultimately, the drug discovery process must be a collaborative one, drawing together researchers from industry, academia, and government agencies to identify and address all possible benefits and consequences. In that spirit, our top-notch speaking faculty brings together experts from all these groups to add
Jennifer McGinnis

Lilly’s pemetrexed (Alimta) offers potential improvements in the treatment of non-small cell lung cancer (NSCLC)

20 May 04

DailyUpdates 20th April: Nearly 423,000 new cases of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are expected to have been diagnosed in the seven major pharmaceutical markets in 2003. Despite the high level of pharmaceutical interest, there are significant unmet needs in the disease in terms of poor survival. Docetaxel is the only drug currently approved in both the U.S. and Europe to treat patients with non-small cell lung cancer in the second-line setting. While the dr

NicOx’s nitro-derivative of naproxen, HCT 3012, shown to be effective in a model of myocardial infarction

11 May 04

DailyUpdates 11th May: A number of clinical studies including the VIGOR trial have suggested that the NSAID naproxen may reduce the incidence of myocardial infarction. However the gastrointestinal side-effects of naproxen and its ability to exacerbate hypertension preclude its use in at-risk individuals. Upcoming data about to be published in the journal JPET demonstrate the efficacy of the safer and anti-hypertensive nitro-derivative of naproxen, HCT 3012, in a model of myocardial infarction.

Results from the PACES trials provides further good news for Pfizer’s Celebrex (celecoxib)

10 May 04

DailyUpdates 10th May: Last week European regulators affirmed the safety of Celebrex; good news for Pfizer continues with the emergence of data from the PACES trials reporting that, compared to acetaminophen, Celebrex is both preferred by patients and is of greater efficacy.

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.